General Information of Drug (ID: DMYPQT4)

Drug Name
4SCAR19 and 4SCAR123 Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMYPQT4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [2]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [3]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [4]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [5]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [6]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [7]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [8]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [9]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [10]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tagraxofusp DM9HQ5U Acute myeloid leukaemia 2A60 Approved [12]
CD123/CLL1 CAR-T Cells DM45Z3P Acute myeloid leukaemia 2A60 Phase 2/3 [13]
Talacotuzumab DMARVFG Acute myeloid leukaemia 2A60 Phase 2 [14]
MB-102 DMLPNVS Acute kidney injury GB60 Phase 2 [14]
Flotetuzumab DMVR6OM Acute biphenotypic leukaemia 2B33.4 Phase 2 [14]
SAR440234 DM6M8O4 Acute myeloid leukaemia 2A60 Phase 1/2 [15]
CD123-specific gene-engineered T cells DMHOWU5 Acute myeloid leukaemia 2A60 Phase 1/2 [16]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [17]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [18]
Anti-CD123-CAR-transduced T cells DMFV6TY leukaemia 2A60-2B33 Phase 1/2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]

References

1 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
8 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
9 Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
10 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
11 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
12 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13 ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
16 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
17 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
18 ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
19 ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies